Trials Currently Looking for Patients
AZURE D7960C00015 (Astra Zeneca)
Patients with LDL (bad cholesterol) over 100, and other risk factors like diabetes, smoking and high blood pressure
OCEAN(a) 20230222 (Amgen)
PACIFIC D6972C00002 (Astra Zeneca)
Looking for patients with high blood pressure and kidney disease with protein in their urine
Current Clinical Trials
PREVAIL TA-8995-304 (New Amsterdam) 20604 (Bayer) Phase III January 2023-Present
Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies. NCT05202509
GARDEN-TIMI 74 C3651011 (Pfizer). Phase II September 2022-Present
A Phase 2, double blind, randomized, placebo-controlled, 4 arm study to investigate symptoms, function, health-related quality of life and safety with repeated subcutaneous administration of prosegromab versus placebo in adult participants with heart failure. NCT05492500. **First Site to Enroll a Patient in the United States**
MARITIME-CV (AMGEN)-Indication:
ROXI-ATLAS (Regeneron)- Indication:
Atrial Fibrillation/Flutter and willing to take anticoagulant therapy
EASi-PROTKT (Boehringer Ingelheim)-Indication:
Type 2 Diabetes, Hypertension, History of Cardiovascular Disease without Heart Failure
HERMES (Novo Nordisk)-Indication:
Heart Failure with Preserved Ejection Fraction > 40% and elevated hs-CRP (inflammatory marker lab)
Dal-GenE-2 (DalCor Pharmaceuticals)- Indication:
MI (Heart Attack) with in the past 90 days
AMBER HFpEF (Cytokinetics)-Indication:
Ages 40 years to 85 years with Heart Failure with Preserved Ejection Fraction > 60%
BalanceD-HF (AstraZeneca)-Indication:
Chronic Kidney Disease, History of Heart Failure with Hospitalization or Urgent Care Visit for heart failure requiring IV medications for treatment within the past 6 months.
